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Abstract 
Objective: To identify research priorities in the management, epidemiology, outcome and underlying causes of 
sepsis and septic shock.
Design: A consensus committee of 16 international experts representing the European Society of Intensive Care 
Medicine and Society of Critical Care Medicine was convened at the annual meetings of both societies. Subgroups 
had teleconference and electronic‑based discussion. The entire committee iteratively developed the entire document 
and recommendations.
Methods: Each committee member independently gave their top five priorities for sepsis research. A total of 88 
suggestions (ESM 1 ‑ supplemental table 1) were grouped into categories by the committee co‑chairs, leading to the 
formation of seven subgroups: infection, fluids and vasoactive agents, adjunctive therapy, administration/epidemiol‑
ogy, scoring/identification, post‑intensive care unit, and basic/translational science. Each subgroup had teleconfer‑
ences to go over each priority followed by formal voting within each subgroup. The entire committee also voted on 
top priorities across all subgroups except for basic/translational science.
Results: The Surviving Sepsis Research Committee provides 26 priorities for sepsis and septic shock. Of these, the 
top six clinical priorities were identified and include the following questions: (1) can targeted/personalized/precision 
medicine approaches determine which therapies will work for which patients at which times?; (2) what are ideal end‑
points for volume resuscitation and how should volume resuscitation be titrated?; (3) should rapid diagnostic tests 
be implemented in clinical practice?; (4) should empiric antibiotic combination therapy be used in sepsis or septic 
shock?; (5) what are the predictors of sepsis long‑term morbidity and mortality?; and (6) what information identifies 
organ dysfunction?
Conclusions: While the Surviving Sepsis Campaign guidelines give multiple recommendations on the treatment of 
sepsis, significant knowledge gaps remain, both in bedside issues directly applicable to clinicians, as well as under‑
standing the fundamental mechanisms underlying the development and progression of sepsis. The priorities identi‑
fied represent a roadmap for research in sepsis and septic shock.
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Introduction
Sepsis is life threatening organ dysfunction caused by 
a dysregulated host response to infection [1]. Sepsis is 
a global public health emergency, affecting millions of 
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people worldwide, and representing one of the largest 
causes of death across the world [2].
The Surviving Sepsis Campaign is dedicated to reduc-
ing mortality from sepsis. The campaign has released 
four sets of guidelines over the last 14  years, with the 
most recent being published in 2016 [3]. The 2016 Sur-
viving Sepsis Guidelines consist of 93 statements on the 
early management and resuscitation of sepsis and septic 
shock, of which 32 are strong recommendations (7 based 
upon high evidence, 21 based upon moderate evidence 
and 4 based upon low evidence), 39 are weak recommen-
dations (7 based upon moderate evidence, 32 based upon 
low or very low evidence) and 18 are best practice state-
ments. Following recommendations contained within 
the Surviving Sepsis guidelines has been associated with 
improved outcomes [4, 5]. However, gaps in the data 
frequently exist, leading to insufficient clarity on many 
elements of sepsis management and precluding recom-
mendations on many topics. Notably, the Surviving Sep-
sis Campaign guidelines are designed to assist bedside 
practitioners in the treatment of patients with sepsis and 
septic shock and therefore are restricted solely to man-
agement issues.
In an attempt to determine priorities for research 
within the field of sepsis, the Surviving Sepsis Campaign 
created a research committee that was explicitly charged 
with developing a list of research priorities related to 
sepsis. The intention was to address all aspects of sepsis. 
Thus while bedside management of sepsis played a key 
role, the committee also covered topics that are not part 
of the guidelines, including fundamental mechanisms 
underlying the development and progression of sepsis 
and septic shock. Understanding that possibilities for 
research within the broad field of sepsis are nearly limit-
less, the goal of this document is for the Surviving Sepsis 
Campaign to identify research priorities for improving 
understanding of and outcomes from sepsis.
Methods
Sponsorship
Funding for the research priorities was provided solely by 
SCCM and ESICM. No outside funding was received.
Selection and organization of the committee
The presidents of ESICM and SCCM appointed seven 
members (including one co-chair DDB and CMC, 
respectively) from each society in 2016 to the committee. 
In addition, the co-chairs of the Surviving Sepsis Cam-
paign guidelines (LE, AR) were added as ad hoc mem-
bers to the committee. Committee members were chosen 
based upon expertise in a wide variety of topics related 
to sepsis. As such, while many of the members of the 
research committee were authors on the Surviving Sepsis 
Campaign guidelines, many were not authors, so as to 
include expertise in areas not covered within the guide-
lines. In keeping with a commitment to diversity from 
both SCCM and ESICM, diversity (broadly defined but 
including geographic, gender, profession, specialty, socio-
economic) was expressly considered when populating the 
committee.
Determination of research questions and priorities
Each task force member was asked to submit five 
research questions on any subject related to sepsis. 
Respondents were instructed to pick the topics they felt 
were most important, explicitly not restricting this to any 
particular area. As such, the questions were not limited 
to areas of patient management (as covered by the Sur-
viving Sepsis Campaign guidelines [3]) or definitions (as 
covered in the recent Sepsis 3 definitions [1]). The expec-
tation was this open-ended approach would yield ques-
tions spanning the entire potential gamut of research 
related to sepsis. A total of 88 questions were narrowed 
to 26 questions (Fig. 1) based upon a voting prioritization 
process detailed in supplemental methods ESM 2.
The entire committee was subsequently asked to rank 
their top three research priorities in order from all sub-
groups except basic/translational science. The reason 
for excluding the basic/translational subgroup from the 
ranking of research priorities is the committee did not 
feel it was possible to directly compare the other six sub-
groups (which relate to critically ill patients at the bed-
side currently) to the more mechanistic and fundamental 
questions asked in basic/translational science (which 
relate to understanding sepsis better but cannot be used 
at the bedside currently). Choices were weighted so that 
each respondent’s first choice was worth three points, 
second choice was worth two points and third choice was 
Fig. 1 Flowchart identifying process of narrowing to top research 
questions
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worth one point. The initial goal was to generate a top 
five priority list; however, a three-way tie for the fourth 
place resulted in the final top six priority list (Fig. 1). Of 
note, nine different questions received a first choice vote. 
A total of 13/16 first choice votes are represented in the 
top six priorities, and no question outside of the top six 
priorities received more than two votes total (and no 
question outside of the top six received more than a sin-
gle first choice vote).
Conflict of interest policy
No industry input into the research priorities was 
obtained, and no industry representatives were present 
at any point in the process. No members of the research 
committee received financial compensation or honoraria 
of any type for their participation on the committee.
The process relied on personal disclosure in an identi-
cal manner to the Surviving Sepsis Campaign guidelines. 
No attempt was made by the group to seek additional 
information on self-reported conflict of interest.
Results
Top six research priorities
While each of the 26 research questions below were 
felt to be important (ESM 3), the committee felt it was 
appropriate to include a list of the top priorities distinct 
from basic/translational science. A list of the top six 
research priorities was therefore generated based upon 
a vote of the entire committee (Table 1). These priorities 
are not presented in order of importance, as we did not 
attempt to discriminate the relative importance of the 
top six research priorities. Although there was no intent 
to highlight any specific subgroups in the top priorities, 
they were nearly evenly distributed from the subgroups 
including infection (two priorities), fluids and vasoac-
tive agents, adjunctive therapy, scoring/identification, 
and post-intensive care unit. The only subgroup that was 
not represented was administration/epidemiology. Since 
basic/translational science was felt to be distinct enough 
as to not be comparable, the four questions in this group 
(Table  2) were not ranked but are felt to be of equal 
importance in a complementary fashion.
Infections
Should empiric antibiotic combination therapy be used 
in sepsis or septic shock?
What is known Early institution of adequate antimicro-
bial therapy is associated with decreased mortality in 
septic patients [6, 7]. Combination therapy is defined 
herein as the use of two different classes (usually of dif-
ferent mechanistic classes) of antimicrobial agents for a 
single pathogen. There are two possible reasons for using 
combination therapy—(a) to accelerate pathogen clear-
ance rather than to broaden antimicrobial coverage or (b) 
to assure that one pathogen is sensitive to the antibiotic, 
in light of significant microbial resistance. The most com-
mon therapy combinations include a beta-lactam with 
an aminoglycoside, fluoroquinolone or macrolide. It is 
important to note that sensitivity of microbes to these 
antibiotics varies locally, and this should be taken into 
account prior to prescribing combination therapy. Com-
bination therapy must be distinguished from broad spec-
trum antibiotics (i.e. a single gram positive agent, a single 
gram negative agent, a single anti-fungal agent).
A propensity-matched analysis and a meta-analysis/
meta-regression analysis have been performed examining 
the efficacy of combination therapy when used to accel-
erate pathogen clearance [8, 9]. These show improved 
survival in patients with a mortality risk of greater than 
25% but also suggest the possibility of increased mortality 
in patients with lower-risk of death (< 15%). Based upon 
this, the Surviving Sepsis Campaign guidelines suggest 
the use of combination therapy for the initial manage-
ment of septic shock (weak recommendation, low qual-
ity of evidence) and suggest against routine combination 
therapy for sepsis without shock or for bacteremia (weak 
recommendation, low quality of evidence).
It should be noted, however, that there are signifi-
cant conflicting data regarding combination therapy 
in bacteremia, sepsis without shock and septic shock. 
A randomized, open-label, parallel-group trial of 600 
patients with sepsis or septic shock treated with mono-
therapy or combination therapy did not demonstrate a 
Table 1 Top research priorities
Can targeted/personalized/precision medicine approaches determine 
which therapies will work for which patients at which times?
What are ideal endpoints for volume resuscitation and how should 
volume resuscitation be titrated?
Should rapid diagnostic tests be implemented in clinical practice?
Should empiric antibiotic combination therapy be used in sepsis or 
septic shock?
What are the predictors of sepsis long‑term morbidity and mortality?
What information identifies organ dysfunction?
Table 2 Basic science questions
What mechanisms underlie sepsis‑induced cellular and sub‑cellular 
dysfunction?
How does sepsis alter bio‑energetics and/or metabolism (both enhance‑
ment and failure)?
How does sepsis (and/or approaches used to manage sepsis) alter phe‑
notypes and interactions in the host microbiome and do alterations in 
the microbiome effect outcomes
What mechanisms initiate, sustain and terminate recovery?
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change in organ failure or mortality between the two 
groups [10]. A recent meta-analysis of empirical mono-
therapy vs combination therapy for adult ICU patients 
with sepsis showed no difference in mortality or other 
patient-important outcomes, although the quantity and 
quality of data was low [11]. Similarly, a meta-analysis 
of monotherapy versus beta lactam-aminoglycoside 
combination therapy for sepsis found no difference in 
mortality but an increase in nephrotoxicity in the com-
bination therapy group [12]. This is consistent with a 
subsequent study from the Netherlands (which has a 
low prevalence of antimicrobial resistance) of a short 
course (median length 2  days) of adjunctive empirical 
therapy in patients with sepsis and septic shock which 
found an increased incidence of renal failure but not 
with improved survival in patients receiving combina-
tion therapy [13]. This has led some experts to support 
using two agents in empiric treatment for septic shock 
but to de-escalate to monotherapy once susceptibilities 
become available [14] or to call for more evidence in 
light of the theoretical benefits of targeted combination 
therapy but the mix of supporting and non-supporting 
data and overall insufficient data [15].
Gaps in knowledge/critique of evidence While numer-
ous observational trials have been performed examining 
combination therapy [16–20], no well-done randomized 
controlled trial has examined this approach in sep-
tic shock patients. Although the most recent Surviving 
Sepsis guidelines recommend combination therapy for 
septic shock (and not for sepsis) based upon these avail-
able studies for accelerated pathogen clearance [3], the 
evidence to support this recommendation was assessed 
as “low quality”. The issue of broadening antibiotic cov-
erage was not covered in the Surviving Sepsis guide-
lines. Guidelines on management of hospital-acquired 
and ventilator-associated pneumonia suggest combina-
tion therapy in some specific settings to assure that the 
infecting pathogen is sensitive to at least one antibiotic, 
but the evidence to support this weak recommendation 
was based upon “low-quality evidence” for ventilator-
associated pneumonia and “very low-quality evidence” 
for hospital-acquired pneumonia [21]. Whether these 
apply to sepsis for non-pulmonary sources remains to be 
determined.
Future directions Adequately powered randomized 
controlled trials should directly test whether combi-
nation therapy is beneficial in order to decrease mor-
tality in sepsis and septic shock. These studies should 
address whether combination therapy is beneficial when 
used to accelerate pathogen clearance. Separately, stud-
ies should be performed to determine whether this 
approach is beneficial when used to assure that one 
pathogen is sensitive to a prescribed antibiotic and not 
when used for synergistic purposes related to pathogen 
clearance. Since not all combinations would potentially 
be expected to have equivalent efficacy [22, 23], differ-
ent antibiotic combinations should be tested to deter-
mine if some combinations are more effective than 
others or more effective than monotherapy. It is critical 
to note study results may be different based upon local 
antibiotic resistance patterns and thus must be per-
formed in different settings.
Does optimization of antimicrobial pharmacokinetics 
and pharmacodynamics impact patient outcomes in sepsis?
What is known Antimicrobial pharmacokinetics (PK) and 
pharmacodynamics (PD) are important considerations 
for antibiotic success, which may be particularly relevant 
in critically ill patients with sepsis and septic shock [24, 
25]. The pathophysiologic changes that occur in sepsis 
can have a major effect on PK by increasing volume of 
distribution as well as augmenting clearance, resulting in 
underdosing of antibiotics administered at conventional 
doses. Further, drug metabolism varies significantly in 
critically ill patients with sepsis which may result in fail-
ure to achieve PD targets for antimicrobials, and hence 
bacteriological cure. It may also promote emergence of 
antibiotic resistance.
Gaps in knowledge/critique of evidence Both dosing 
and timing recommendations for antibiotics are pre-
dominantly based on studies performed in the general 
population which limits their applicability in the clinical 
setting in patients with sepsis and septic shock where 
both PK and PD would be expected to be altered [26]. 
Even though several studies report alterations in PK/
PD in patients with septic shock, the impact of this on 
bacteriological cure and outcome remains to be deter-
mined. Alternative approaches to conventional anti-
microbial management include the use of extended or 
continuous administration of some antibiotics and/or 
higher doses. However, the risk/benefit profiles of these 
approaches have not been clearly established.
Future directions The factors associated with PK/PD 
variability to consider in critically ill patients with sep-
sis and septic shock need to be determined. The impact 
and cost-effectiveness of incorporating therapeutic 
drug-monitoring into daily clinical practice to adjust 
antibiotic dosing in patients with sepsis and septic 
shock needs to be determined. In addition, studies are 
necessary to ascertain whether continuous/extended 
infusion of β-lactams and/or higher doses of antibi-
otics provide a better bacterial cure and improve out-
come. If so, research should determine whether these 
approaches should be used in all septic patients or only 
in a subset of selected patients. Ideally, an approach 
could be utilized in which antibiotic dosing in patients 
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with sepsis could be determined based on clinical char-
acteristics and source of infection. If this is possible, it 
leads to the fundamental question about whether it is 
possible to individualize antibiotic dosing regimens for 
septic patients.
Should antiviral therapy be administered in the 
context of viral reactivation in patients with acquired 
immunosuppression?
What is known The immune response is commonly 
altered in septic patients [27], and there is growing evi-
dence that critically ill patients may present with a state 
of acquired immune deficiency (sometimes referred to 
as immunoparalysis) [28]. Healthy people are frequently 
asymptomatically infected by viruses that can subse-
quently persist in a latent state. For instance, cytomegalo-
virus (CMV) infects approximately 50–80% of otherwise 
healthy adults, who have lifelong latency in multiple cell 
types following their initial asymptomatic infection [29]. 
Several studies have reported reactivation of viruses in 
critically ill patients that do not have a prior history of 
being immunocompromised, and this is associated with 
worse outcomes in critical illness [30, 31]. Notably, in a 
study of 560 critically ill septic patients, 161 critically-ill 
non-septic patients and 164 age-matched healthy con-
trols, cumulative viral DNA detection rates in the blood 
included CMV (24%), Epstein–Barr (53%), herpes sim-
plex (14%), human herpes virus-6 (10%) and TTV (78%) 
despite these being uncommon in both critically-ill non-
septic patients and healthy controls [32]. Notably, 42.7% 
of septic patients had two or more viruses. These are 
consistent with studies specifically looking at CMV in 
the ICU which demonstrate active rates of 17% in non-
immunosuppressed patients, mostly occurring between 4 
and 12 days after ICU admission [33, 34].
A recent trial of 160 CMV-positive patients with sepsis 
or trauma randomized participants to receive ganciclovir 
or placebo. Despite lower levels of CMV reactivation in 
the treatment group, no difference was noted in the pri-
mary outcome (IL-6 levels) although ventilator free days 
were higher in the treatment group [35]. In contrast, 
a single center trial of 124 CMV-seropositive patients 
undergoing mechanical ventilation randomized patients 
to receive anti-CMV prophylaxis with valacyclovir or 
low-dose valganciclovir. While valacyclovir decreased 
viral reactivation in the blood (12 patients vs. 2 patients), 
this finding was associated with an increase in 28-day 
mortality in patients receiving valacyclovir (41.2% in 
treatment arm vs. 13.5% mortality in control arm) [36].
Gaps in knowledge/critique of evidence Viral reacti-
vation has been shown to be associated with a worse 
outcome but it is unclear whether the increased risk of 
death is related to the underlying condition or whether 
the viral reactivation itself contributes to the increased 
risk of death. The role—if any—of either prophylaxis or 
treatment of CMV reactivation is not clear, being limited 
to small studies. Further, the role of prophylaxis or treat-
ment of viral infections outside of CMV is understood 
even less.
Future directions Randomized controlled trials should 
be performed to delineate the role (if any) of prophy-
laxis against viral reactivation. Similar trials should be 
performed to determine if treatment, once viral reacti-
vation occurs, confers any benefit in altering mortality 
and/or other patient-centric outcomes. If either strategy 
is beneficial, it needs to be clarified whether prophylaxis 
or treatment is beneficial in all septic patients or only in 
a subset. Further, studies need to delineate whether spe-
cific viruses (CMV, EBV, HSV, HHV-6, TTV) carry thera-
peutic or prognostic significance. These studies should 
answer the question whether viral reactivation plays a 
role in mediating poor outcomes or is simply a marker of 
worse outcomes.
Should rapid diagnostic tests be implemented in clinical 
practice?
What is known Sepsis is a time-sensitive condition, with 
delays in either diagnosis or therapy leading to increased 
mortality. Faster diagnosis of sepsis could potentially 
reduce mortality, shorten length of stay, and lower hos-
pital costs [37, 38]. However, diagnosis of sepsis relies 
upon a clinician suspecting infection without the actual 
ability to diagnose infection in real time. A significant 
number of patients with sepsis never have positive cul-
tures. In addition, even in patients whose cultures will 
ultimately be positive, there is a time lag of hours to 
days between when the sample is sent to when the posi-
tive result is obtained. Further, outside of the potential 
utility of biomarkers such as procalcitonin, there is lit-
tle available to the clinician to determine if the infection 
has resolved. The inability to rapidly diagnose infection 
and/or to determine when the infection has cleared can 
lead to widespread usage of broad spectrum antibiotics 
[39]. Notably, despite advances in the technology avail-
able to treat septic patients, culturing techniques used 
for identifying infection have not changed substantially 
over a number of decades. Numerous rapid diagnostic 
tests have been tested in patients for the identification 
of infection. Further, numerous biomarkers have been 
tested for the identification or prognostication of sepsis 
(covered elsewhere in this manuscript).
Gaps in knowledge/critique of evidence Identifica-
tion of the causative organism has traditionally involved 
phenotypic analysis of organisms isolated from positive 
cultures. However, this process can take days, during 
which time patients may be treated with broad-spectrum 
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antibiotics until positive pathogen identification becomes 
available (which may never happen considering that 
many septic patients are culture negative). In addition, 
it is sometimes difficult to obtain samples. For instance, 
sputum is not always available in septic patients with 
pneumonia who are not intubated, and peritoneal fluid 
is not always accessible in septic patients with peritoni-
tis. Faster and more accurate pathogen identification is 
therefore critical [40, 41]. When a culture is flagged as 
positive a gram stain is performed that can potentially 
provide information about the type of organism respon-
sible for the infection; however, this does not provide an 
acceptable level of accuracy to guide therapy. Instead, 
tailored therapeutic intervention relies on identification 
of species, which can take days using conventional tech-
niques, and the antibiotic resistance profile will typically 
be available only 1–2 days after that. Further, detection of 
fungi, viruses, and anaerobic bacteria can be more chal-
lenging than detecting aerobic bacteria, both in terms 
of timing and sensitivity. Several methods to detect the 
implicated pathogen (bacterial DNA detection, syn-
dromic PCR) and detection of resistant organisms and/
or rapid antibiogram have recently developed [42–45]. 
Unfortunately, none of these techniques has been widely 
adopted due to a combination of factors including (but 
not limited to) cost, logistics and accuracy concerns.
Future directions Future research should evaluate 
whether existing rapid diagnostic tests facilitate diag-
nosis and should be implemented in clinical practice. If 
so, studies need to determine which techniques and/
or methods are superior or if further optimization is 
required, which may require both technological advances 
and examination of test accuracy across a variety of 
resource settings. Importantly, the role of rapid diagnos-
tic tests in antibiotic stewardship (when to start, how 
broad, when to de-escalate, when to stop) needs to be 
examined. Further, although it is logical to believe that 
rapid diagnostic tests could potentially change patient 
outcomes, this assumption should be formally tested. 
Finally, assessing the immune system and performing 
rapid diagnostic tests might potentially help identify 
both the infecting organism and the dysregulated host 
response simultaneously, and an integrative approach 
examining both microbe and host may yield critical 
insights that assaying each in isolation might miss.
Fluids and vasopressors
What are ideal endpoints for volume resuscitation and how 
should volume resuscitation be titrated?
What is known The administration of intravenous fluids 
to improve circulation, perfusion, and oxygen delivery is a 
fundamental principle in sepsis management [46]. How-
ever, the potential benefits of administering fluid must be 
balanced against the potential for harm due to the accu-
mulation of fluid, such as, pulmonary edema, abdomi-
nal compartment syndrome, and tissue edema. Current 
recommendations from the Surviving Sepsis Campaign 
suggest resuscitating patients with sepsis-induced hypop-
erfusion with at least 30  ml/kg of IV crystalloid within 
the first 3 h [3]. The Surviving Sepsis bundles have been 
associated with improved survival in numerous large-
scale studies [4, 6, 47], although the specific importance 
of each individual component of the bundle is unclear. It 
should be noted that while more rapid completion of the 
3  h bundle and rapid administration of antibiotics was 
associated with improved outcome in a study of nearly 
50,000 patients, a longer time to completion of initial 
fluid bolus was not associated with a change in mortal-
ity [6]. Further, the amount of fluid administered was not 
associated with survival differences in observational and 
randomized studies of early goal directed therapy [48]. 
Also, an early resuscitation protocol including intrave-
nous fluids, vasopressors, blood transfusion and invasive 
monitoring was associated with increased mortality com-
pared to usual care in patients with sepsis (mostly HIV) 
and hypotension in a developing country [49].
The fundamental reasoning for administering fluid is 
to improve tissue perfusion by increasing cardiac out-
put [50]. Traditional approaches to titrating fluid admin-
istration have been based on static measures of preload 
[51]. Dynamic indices of preload may better predict the 
response to fluids but still remain underused [52]. How-
ever, there are instances where a patient will not improve 
despite the administration of fluids. Identifying robust 
clinical parameters that distinguish patients likely to 
positively respond to a fluid bolus from those unlikely to 
respond is an essential need in sepsis care. One impor-
tant caveat to mention is that while there is inherent 
value in determining which patients will respond to fluid 
boluses, it is unclear whether this will result in improved 
outcomes.
Gaps in knowledge/critique of evidence Current 
approaches to determine fluid responsiveness include 
the application of empiric fluid boluses, static measure-
ments, and dynamic markers. The empiric administra-
tion of a fluid bolus to determine fluid responsiveness 
is inherently troublesome since a substantial number of 
patients will not respond, potentiating harm. The worst 
case scenario is when this empiric administration is done 
without any measurement of effectiveness and tolerance 
which can often lead to repeat administration when the 
problem triggering fluid administration persists.
Static measures involve the placement of venous cathe-
ters to facilitate the measurement of central venous pres-
sure (CVP) and pulmonary capillary occluded pressure 
(PAOP) and evaluate baseline and incremental changes 
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in pressure following fluid administration. However, fluid 
responsiveness on the basis of CVP has not consistently 
demonstrated validity as a measure of fluid responsive-
ness [53]. Dynamic measures include a variety of tech-
niques to assess the change in cardiac output in response 
to transient changes in preload induced by ventilation or 
an external maneuver, prior to fluid administration. Com-
mon types of dynamic measures used in clinical practice 
include passive leg raise (PLR) maneuver, respiratory var-
iation, pulse pressure variation (PPV), and stroke volume 
variation (SVV) [54]. However, variations in respiratory 
patterns or pulse pressure and stroke volume can be dif-
ficult to interpret in spontaneously breathing patients. 
PLR is most useful when a rapid-response cardiac output 
monitoring is available [55], but still requires rigorous 
investigation and testing.
Importantly, the determination of triggers to admin-
ister fluids after initial resuscitation as well as triggers 
to stop fluid resuscitation remain poorly understood. 
While there is a significant literature evaluating many of 
these methods in the peri-operative setting and in non-
selected critical care patients, there is a paucity of litera-
ture comparing the various methods for assessing fluid 
responsiveness in patients with sepsis/septic shock. In 
these patients the validity of these tests may be impaired 
due to the impact of vasoplegia, use of low tidal volume 
ventilation and presence of respiratory movements or 
increased abdominal pressure. Furthermore, application 
and translation of these findings across all types of clini-
cal settings is necessary. This includes developed coun-
tries in settings where minimal monitoring devices can 
be implemented (i.e. hospital wards) as well as low- and 
middle-income countries which account for a majority of 
all cases of sepsis worldwide. Clinical utility of tests for 
fluid responsiveness need to be reproducible and applica-
ble in resource-limited settings.
Future directions While great progress has been made 
in the clinical investigation of fluid resuscitation, press-
ing uncertainties remain leading to the following core 
questions: (a) do ideal clinical parameters and endpoints 
for volume resuscitation exist; (b) how should volume 
resuscitation be titrated; (c) what is the optimal dose of 
initial volume bolus administration; and (d) how should 
the approach for volume resuscitation be modified in 
resource-limited settings?
In the course of routine clinical care, physiological 
parameters are explicitly framed to direct the admin-
istration of any therapy (e.g. anti-hypertensives for the 
treatment of hypertension). In contrast, ideal physiologi-
cal parameters to outline therapeutic endpoints for fluid 
resuscitation, titration, and amount of volume are largely 
unknown and remain ambiguous. Traditional approaches 
of 30 ml/kg of initial volume bolus were founded over a 
decade ago, and dictate a “one size fits all” strategy of ini-
tial fluid administration [56]. While there is benefit to a 
standardized approach to initial fluid resuscitation (espe-
cially for clinicians relatively inexperienced in the man-
agement of septic patients), the ideal approach would be 
personalized pending on individual patient need.
Subsequent fluid administration is even more compli-
cated and is often driven by various approaches The need 
to identify the optimal measures of fluid responsiveness 
directly influences the clinician’s ability to determine if 
further volume administration may be beneficial and if 
the patient is likely to positively respond to fluids, and 
how therapy should be titrated (which amount/speed of 
infusion/stopping rules). Randomized, controlled trials 
are needed to determine if greater precision is possible to 
determine how much fluid can be administered as a sin-
gle dose for a given patient. Additionally, these questions 
and approaches should be tested to identify the optimal 
approach in resource-limited settings. Finally, studies 
evaluating clinical endpoints for resuscitation should be 
tested in a pragmatic design to promote diffusion of find-
ings and rapid uptake into clinical practice, particularly 
in resource-limited settings.
What is the optimal fluid for sepsis resuscitation?
What is known Broadly stated, large randomized, con-
trolled, multicenter trials have found no significant differ-
ence between albumin and crystalloids. The Saline versus 
Albumin Fluid Evaluation (SAFE) study found no differ-
ence in 28-day mortality for patients randomized to 0.9% 
normal saline or 4% albumin, although there was a trend 
towards improved outcomes in the study for patients 
with sepsis in a post hoc subgroup analysis [57]. Mor-
tality was also not different between patients receiving 
20% albumin or crystalloid in a large randomized trial in 
patients with sepsis or septic shock (ALBIOS trial) [58]. 
However, while the overall study did not show a differ-
ence in outcome, subgroup analysis showed improved 
mortality in patients with septic shock. Multiple meta-
analyses have been performed comparing albumin to 
crystalloid, although different populations have made 
combining the data challenging [59]. Together, these have 
led to a weak recommendation (based upon low quality 
evidence) in the Surviving Sepsis Campaign for using 
albumin in addition to crystalloids for both initial resus-
citation and subsequent intravascular volume replace-
ment in patients with both sepsis and septic shock who 
require substantial amounts of crystalloid [3]. Within 
the context of the broader categories of crystalloids and 
colloids, there exist distinctions between individual fluid 
choices [60, 61]. Hydroxyethyl starch should not be used 
on the basis of the increased risk for acute kidney injury 
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and need for renal replacement therapy, in addition to 
increased mortality in many meta-analyses [62–65].
There is developing interest in administering crystal-
loids with a balanced ion content to reduce the chloride 
load observed with 0.9% normal saline [66]. Crystalloid 
solutions, such as, Ringer’s lactate and PlasmaLyte, have 
been studied with varying results [67]. Lactate-based 
chloride-free solutions have been developed and can 
improve cardiac output and blood pressure while achiev-
ing a negative fluid balance [68]. While numerous smaller 
studies have demonstrated benefit in balanced crystal-
loids, a randomized controlled comparing 0.9% normal 
saline to PlasmaLyte did not reduce the risk of acute 
kidney injury [69]. However, while this study is widely 
quoted, the majority of the patients were admitted fol-
lowing elective surgery, had relatively few co-morbidities, 
received a relatively small amount of fluid, were not sep-
tic, and the overall mortality was low. As such, the rel-
evance of this study to septic patients is unclear. Recently, 
two large randomized controlled trials compared bal-
anced crystalloids to 0.9% normal saline in 15,802 criti-
cally ill patients from 5 ICUs and 13,347 non-critically ill 
emergency department patients who were subsequently 
hospitalized outside of the ICU [70, 71]. In critically ill 
patients, balanced crystalloids resulted in a statistically 
significant 1.1% decrease in the composite outcome of 
death from any cause, new renal-replacement therapy or 
persistent renal dysfunction. While balanced crystalloids 
did not change the primary outcome of hospital free days 
in non-critically ill patients, they were associated with a 
statistically significant 0.9% decrease in the composite 
outcomes of major adverse kidney events seen in criti-
cally ill patients. Although a subgroup analysis showed 
a larger decrease (5.1%) in composite outcome in septic 
patients given balanced crystalloids, it is important to 
note that patients with sepsis or septic shock represented 
less than 15% of the ICU patients in this study [70]. Fur-
ther, the percent of septic patients was not reported in 
the study on non-critically ill patients [71]. As such the 
applicability of these results to septic patients (who often 
require a greater amount of fluids, and suffer from a 
higher incidence of kidney dysfunction and have a higher 
risk of death) remains to be determined.
Gaps in knowledge/critique of evidence Existing trials 
have not sufficiently evaluated fluid administration in 
the full continuum of acute sepsis, including initial fluid 
resuscitation, subgroups of patients, and adequately con-
trolling for bias. While the detrimental effects of small 
amounts of any given fluid are often negligible, significant 
adverse effects may arise when large amounts are admin-
istered. Many of the trials that have been conducted have 
administered very limited amount of fluids so that these 
concluded that no difference was detected. Furthermore, 
as the burden of sepsis is better recognized, evaluating 
fluid types that are widely available around the world is 
necessary.
Future directions The choice of fluid in early sepsis 
resuscitation is still largely unknown and needs to be 
delineated. Further, the choice of fluid once initial resus-
citation has been completed is equally unclear. Despite 
numerous studies, the role of colloids is still unclear 
including when to use, how much to use, and type to use. 
Finally, trials distinguishing between balanced crystal-
loids and normal saline are necessary but these should 
mimic the behavior of clinicians and take into account 
chloride measurements and potentially stopping once 
hyperchloremia develops. Given the heterogeneity of sep-
sis etiology, subgroups of sepsis need to be further evalu-
ated to determine if there are specific groups in which 
type of fluid impacts outcomes. Finally, fluid choice in 
resource-limited areas has not been fully described, and 
pragmatically designed trials are required to investigate 
optimal fluids in these settings.
What is the optimal approach to selection, dose titration, 
and escalation of vasopressor therapy?
What is known Norepinephrine has been demonstrated 
to be a superior vasopressor option when compared to 
dopamine in a broad group of patients with shock [72]. 
Epinephrine is also a suitable substitute as a vasopressor 
when inotropy is also required (similar to a combination 
of a norepinephrine and dobutamine). As a non-catecho-
lamine vasopressor, vasopressin has been demonstrated 
to be safe as an adjunct agent to norepinephrine and to 
potentially improve outcome in a subgroup of patients 
with less severe septic shock [73]. Of note, vasopressin as 
a primary agent has been compared to norepinephrine, 
yielding no difference with regards to acute kidney injury 
and failing to confirm the beneficial effects in patients 
with less severe shock [74]. More recently, angiotensin II 
has demonstrated efficacy in raising mean arterial pres-
sure (MAP) but outcome data are still lacking [75]. In 
contrast, non-selective inhibition of nitric oxide synthase 
has been shown to increase mortality [76], highlighting 
that evaluation of vasopressors should not be based solely 
on its hemodynamic effects. Finally, a higher MAP target 
has not been shown to be beneficial in patients in sep-
tic shock, although in a subgroup of patients with severe 
baseline hypertension, targeting a higher MAP is associ-
ated with less need for renal replacement therapy [77].
Gaps in knowledge/critique of evidence Studies designed 
over the past two decades of septic shock research have 
varied in design and in endpoints, making it difficult to 
consistently evaluate different vasopressor agents. Stud-
ies have used varying doses of vasopressor agents, resus-
citation strategies, clinical endpoints, and therapeutic 
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escalation strategies. Trials evaluating the effects of epi-
nephrine were markedly underpowered. Admittedly, 
none of these showed beneficial effects of epinephrine, 
but it remains to be determined whether some sub-
groups of patients may benefit from epinephrine usage. 
A common framework for how vasopressors should be 
studied is lacking. Trials evaluating higher versus lower 
MAP were always above target in the low target groups 
(65  mmHg). Hence, the current recommendations sup-
porting using pressors to maintain MAP at 65 mmHg are 
only supported by observational data.
Future directions Essential questions remain regarding 
vasopressor selection, escalation of therapy, sequencing 
of vasopressor agents, combination regimens, and dose 
titration. Using the broader categories of fluid choices 
(crystalloids and colloids) as an analogy, a therapeutic 
approach comparing a catecholamine (e.g. norepineph-
rine) to a non-catecholamine (e.g. vasopressin, angioten-
sin II) to raise MAP and improve survival is necessary. 
Similarly, the role of epinephrine as a second line agent 
needs to be evaluated. Further, while angiotensin II has 
recently been shown to effectively increase blood pres-
sure in patients with vasodilatory shock that do not 
respond to high doses of conventional pressors, the indi-
cations for this new agent remain to be determined as do 
its effect on outcomes. Defining an acceptable dose range 
of vasopressors for which to escalate therapy vs. initiate a 
second agent is also necessary. To accomplish this effec-
tively requires rigorous investigation into how vasopres-
sors are dosed and titrated. Finally, subgroups of patients 
should be evaluated (heart failure, essential hyperten-
sion), given the predilection of some patients to suffer 
adverse events of hypotension as well as those resulting 
from vasopressor therapy (arrhythmias or acute kidney 
injury).
Adjunctive therapy
Can targeted/personalized/precision medicine approaches 
determine which therapies will work for which patients 
at which times?
What is known In light of the individual variability of 
septic patients, traditional clinical trial results cur-
rently have an inability to predict the response to an 
intervention at the level of an individual. Similarly, 
clinical practice guidelines are based upon a compos-
ite of overall best practice for the greatest number of 
patients. This does not account for individual differ-
ences as an intervention in a trial that showed overall 
benefit could potentially be of no benefit or harm to 
an individual participating, whereas an intervention 
in a trial that showed no benefit could potentially be 
beneficial to a subgroup of participating patients. The 
pathophysiology of sepsis is a complex and dynamic 
process that originates from the host response to 
infection and varies according to (at a minimum) the 
genetic predisposition, immune status, age and co-
morbid conditions of the host, the type of pathogen 
and the site and extent of infection. Recent advance in 
omics (genomics, epigenomics, transcriptomics, pro-
teomics, metabolomics, pharmacogenomics, micro-
biomics) have the potential to revolutionize care by 
assaying the state of an individual [78, 79]. Individual 
insights need not be confined to “omics”-based data, 
however, as important insights can be drawn from eas-
ily interpretable clinical information and by use of big 
data approaches that allow insight from information 
accessible within the ICU that might not be able to be 
processed by a bedside provider [80].
Gaps in knowledge/critique of evidence At present, 
precision medicine for sepsis remains a vision in the dis-
tance [81, 82]. There are considerable amounts of data 
characterizing sepsis patients according to a single bio-
marker, but there are limited data that broadly phenotype 
sepsis patients and no application of these data to influ-
ence patient care [83]. An example of an early attempt 
was the MONARCS trial, where sepsis patients with IL-6 
levels > 1000 pg/mL were targeted for treatment with an 
anti-TNF monoclonal antibody [84]. Similarly, attempts 
at targeting corticosteroid therapy have not been success-
fully reproduced, yet corticosteroids are used frequently 
in patients with septic shock [85, 86]. Precision medicine 
may also rely on clinical signs. As an example, an ideal 
trial on inotropic agent for treating the consequences of 
sepsis-associated myocardial depression should include 
patients with signs of tissue hypoperfusion associated 
with a low or inadequate cardiac output related to an 
impairment in contractility. This is a different approach 
from a recent trial design that included patients in shock 
with minimal (if any) assessment of cardiac output and 
cardiac function [87].
Future directions The first step toward precision medi-
cine in sepsis is characterizing the clinical and biologi-
cal heterogeneity within the syndrome. As one example, 
the immune response in septic patients ranges from an 
exuberant pro-inflammatory cascade to a profoundly 
immunosuppressed phenotype, yet there is currently an 
inability to accurately phenotype patients at the bedside 
to know where an individual patient lies on the immune 
response spectrum. An approach that has potential 
immediate clinical applicability is targeting precision 
use of corticosteroids, to determine the right patient, the 
right time and the right dose, as well as monitoring for 
the right response to therapy.
On a longer horizon, the development of novel 
methods to rapidly immunophenotype patients could 
enable the targeted application of therapies and 
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monitoring of treatment response. Further, the use of 
both omics and big data to understand the individual 
response, combined potentially with the use of in silico 
modeling, has the potential to revolutionize the man-
agement of sepsis.
Determine the efficacy of “blood purification” therapies 
such as endotoxin absorbers, cytokine absorbers 
and plasmapheresis
What is known A number of studies address this diverse 
area, whose common endpoint is the elimination of 
bloodstream substances that are felt to be harmful. Most 
of the studies are relatively small, often have methodo-
logic issues and often concentrate on the elimination of 
mediators as the outcome of interest rather than a clini-
cal outcome such as mortality. A 2013 meta-analysis of 
16 trials concluded that blood purification decreased 
mortality in sepsis compared to no blood purification. 
However, these results were driven mainly by hemop-
erfusion and plasma exchange, and pooling of all tri-
als of blood purification for treatment of sepsis was no 
longer associated with lower mortality after excluding 
trials using polymyxin B hemoperfusion [88]. There is 
also a negative study pending publication using poly-
myxin B hemoperfusion presented at ESICM LIVES 2016 
[89]. Observational data (registries) support the use of 
cytokine hemoadsorption but there are no randomized 
data at this stage.
Gaps in knowledge/critique of evidence A major 
issue is the heterogeneity of the techniques, as results 
obtained with one technique may not apply to the other 
techniques. The most commonly used techniques are 
cytokine hemoadsorption and polymyxin-b hemoper-
fusion, with polymyxin-b hemoperfusion being widely 
used in Asian countries and cytokine hemoadsorption 
being common in Germany. However, there are numer-
ous knowledge gaps including characterizing what can 
be expected from these techniques (short term hemody-
namic vs modulation of host response), characterization 
of the potential adverse effects (optimization of anti-
coagulation, pharmacokinetics of antibiotics), charac-
terization of all molecules removed, and defining which 
patients (if any) may potentially benefit from these tech-
niques and at which time during the evolution of their 
sepsis.
Future directions There is a clear necessity for large, 
well designed, definitive studies in patients with sepsis 
and/or septic shock, especially since blood purification 
strategies are currently being used in highly selective 
places around the world. There is concern that a large 
scale trial including unselected patients would more than 
likely be negative, exposing patients to potential side 
effects of extracorporeal techniques without expected 
benefits. The challenge to design trials include finding 
the correct patient population as well as incorporating 
the potential financial consequences, as these systems are 
costly.
What is the ideal method of delivering nutrition support, 
including route, timing and composition of nutrition support, 
and whether this varies by hemodynamic status?
What is known Variable results have been reported from 
various studies with various methodologies [90–94]. 
Despite nutrition support being available for many 
years, there is limited conclusive evidence favoring any 
aspect of its use. Prior studies have failed to demonstrate 
the efficacy of early parenteral nutrition in critically ill 
patients, and the most recent studies suggest early feed-
ing, whether enteral or parenteral, may be equivalent 
[95]. Comparing early full enteral nutrition with limited 
caloric intake (“trophic feeds”) one large study found only 
small differences in gastrointestinal intolerance without 
evidence of harm or benefit, whereas a smaller, more 
recent retrospective study on patients in septic shock 
suggested that trophic feeds may reduce the duration of 
mechanical ventilation and length of stay in the ICU [93, 
96]. There are similar controversies and inconsistencies 
in the literature regarding micronutrient supplemen-
tation, immunonutrition, assessing feeding tolerance, 
feeding patients in the presence of shock, and goals of 
nutrition support in sepsis [97, 98].
Gaps in knowledge/critique of evidence Questions 
regarding timing (including when to initiate and when 
to stop), composition, dose and route of nutritional sup-
port therapy in sepsis are incompletely understood, as 
most studies have been carried out in a general critical 
care cohort, and not specifically in patients with sepsis/
septic shock. Moreover, many of the studies have high 
risk of bias and are underpowered. Further, several basic 
aspects of enteral nutrition support remain uncertain. It 
is unclear if the proper goal of providing enteral nutri-
tion is to reach a certain caloric goal or if there a supe-
rior target. There is also significant controversy about 
whether feeding tolerance should be measured using gas-
tric residual volume or other indicators and whether this 
is impacted by type of patient (surgical vs. non-surgical). 
There is also a lack of clarity regarding whether nutri-
tion formulas need to be altered in sepsis, such as with 
micronutrient supplementation or immunonutrition for-
mulas. For patients with septic shock, it remains to be 
determined at what dose of vasopressors enteral nutri-
tion can be provided (and if type of vasopressor impacts 
this), if there is a maximum tolerated dose during shock, 
and if there is a benefit to trophic enteral feeding (with or 
without parenteral nutrition) while on pressors. Finally, 
it is unclear how chronic comorbidities (chronic kidney 
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disease, diabetes mellitus, chronic respiratory failure, 
obesity, etc.) alter nutrition needs in sepsis.
Future directions Research should focus individually on 
each variable as best as practicable. A first step may be 
to start with timing of nutrition. Later studies can exam-
ine both dose and composition (including immunonutri-
tion). Studies should be performed in patients with sepsis 
and septic shock to determine the role of hemodynamic 
status on each factor.
What is the role of lung protective ventilation in septic 
patients without ARDS?
What is known Lung protective ventilation (LPV) has 
been proven effective for reducing mortality and reduc-
ing the duration of mechanical ventilation in patients 
with ARDS [99] although aggressive recruitment maneu-
vers and PEEP titration have been associated with 
increased mortality in ARDS [100]. Observational stud-
ies suggest reductions in the development of ARDS with 
LPV use in patients at risk for ARDS but who had not yet 
developed the syndrome [101]. Two meta-analyses sug-
gest that use of LPV in patients without ARDS reduces 
the duration of mechanical ventilation, the risk of pulmo-
nary infection and the duration of hospitalization [102, 
103]. Given the frequency of respiratory failure in sepsis, 
with consequent high risk for developing ARDS and its 
attendant complications of prolonged mechanical venti-
lation and mortality, optimizing the approach to mechan-
ical ventilation could save thousands of lives and reduce 
healthcare costs through reductions in mechanical venti-
lation and ICU stay.
Gaps in knowledge/critique of evidence Current evi-
dence is observational and is not limited to septic 
patients. Controlled trials in related fields such as peri-
operative respiratory management demonstrate benefits 
for the use of LPV in patients without ARDS [104]; how-
ever, their applicability to septic patients is, as yet, unde-
termined. The PReVENT study is currently ongoing to 
examine the role of LPV in critically ill adult patients for 
improving the number of ventilator-free days [105].
Future directions Conducting a definitive clinical 
trial in patients with sepsis (the most common cause of 
ARDS) is of significant importance.
Scoring/identification
What information identifies organ dysfunction?
What is known Clinical criteria for sepsis in the Sepsis 3 
definition are based on a model where the outcome vari-
ables are either mortality or a composite of mortality and 
increased length of ICU stay [1, 106, 107]. The Sequential 
[Sepsis-related] Organ Failure Assessment (SOFA) and 
quick SOFA (qSOFA) are scoring systems that use clini-
cal data as surrogates for organ dysfunction [108]. These 
clinical constructs are based on objective measurements 
that are easily obtained and are linked to outcomes that 
can be the result of clinical decision making (i.e., the 
decision to discharge from the ICU or to withdraw life-
sustaining therapies). Relatively little is known, however, 
about the pathobiology of dysfunction in individual organ 
systems that is associated with these outcomes. Clinical 
identification is based largely on surrogates (e.g., serum 
creatinine, serum bilirubin, blood pressure,  PaO2/FiO2 
ratio, Glasgow coma scale, platelet count, respiratory 
rate). In contrast, a diagnosis such as myocardial infarc-
tion correlates serum markers (troponins, creatinine 
kinase subgroups) to functional studies (wall shortening 
on echocardiography, changes in electrocardiogram pat-
tern) and anatomy (angiography, histology).
Gaps in knowledge/critique of the evidence Organ dys-
function cannot currently be identified with the degree 
of precision needed to create a diagnostic gold standard 
for sepsis similar to that which exists for other diseases. 
Absent such a standard, clinical criteria must be used 
to construct predictive models for sepsis. In the current 
state, these criteria are limited in their ability to differen-
tiate a septic patient from a patient with other disorders. 
In addition, current predictive models are based on out-
comes (mortality, length of stay) that themselves may be 
biased by subjective clinical decisions.
Future directions Studies that address the lack of gold 
standards for sepsis-associated organ dysfunction are 
needed. This will likely require translation of animal 
models of organ dysfunction or human markers with spe-
cific indicators of organ function. Some possible exam-
ples include myocardial wall motion on imaging, renal 
tubular ion pump function, hepatic synthetic pathways, 
real-time assessment of host immune status, histopathol-
ogy, and omics-based expression patterns. The short-
term translational goal will be to correlate functional 
findings with existing clinical markers. Ideally multiple 
independent assessments of organ function would be 
used to try to provide a comprehensive assessment of 
whole organ function. Gold standards for each organ 
would correlate with available clinical findings (labora-
tory, imaging, functional assessment) which would then 
be correlated with clinical outcomes. Clinical criteria for 
sepsis definitions could then be adapted to provide more 
precise identification of organ dysfunction. Long-term, 
markers of organ dysfunction that either do not exist cur-
rently or exist only in the research domain would ideally 
make the diagnosis of organ dysfunction more mecha-
nistic and precise. Finally, although it is reasonable to 
assume that prevention or early treatment of organ dys-
function improves outcome in sepsis, clinical studies 
should test this supposition.
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How can we screen for sepsis in varied settings?
What is known Sepsis is managed in a variety of set-
tings, including high, low and middle-income countries, 
differently-equipped facilities and in and out of hospi-
tal, including pre-hospital transport. Absent a diagnos-
tic gold standard, screening tools must either predict 
important outcomes or correlate with the development 
of a recognizable entity, as a generally agreed clinical pic-
ture of sepsis. The need to avoid missing at-risk patients 
is an important consideration, especially in environments 
where a missed opportunity to intervene may have a 
strong effect on outcomes. Over-triage of patients who 
may not have sepsis or progress to develop sepsis risks 
wasting resources and exposing patients to the risks of 
unnecessary interventional therapies. At the same time, 
under-triage of patients runs the risk of late identifica-
tion, which is associated with increased risk of death. 
Both of these issues are likely exacerbated in resource-
limited environments. The purpose of a good screening 
tool is to identify populations at risk and compel further 
assessment and treatment while ideally excluding those 
not at risk.
Gaps in knowledge/critique of the evidence Although 
the clinical criteria in Sepsis 3 were developed using 
large derivation and validation cohorts, all of the data 
in the primary publication are from high-income coun-
tries [106, 107]. Subsequent studies appear to validate 
the criteria in both low-middle and developing countries 
[109–111], although this is relatively limited in scope. 
There are also two large prospective evaluations of the 
predictive model in the literature from the United States 
and Australia [112, 113]. In addition, goals for a screen-
ing tool may vary by setting, as high-resource environ-
ments might potentially trade under-triage for better 
accuracy, whereas low-resource environments might 
benefit from initial over-triage, so as not to miss high-risk 
cases. Finally, the purpose of the screen—to compel fur-
ther assessment and treatment—has not been adequately 
studied.
Future directions Existing models for sepsis screen-
ing should be refined. Further, there should not be an 
assumption that all environments are the same and that a 
“one size fits all” screening tool will work the same, inde-
pendent of location. As such, the efficacy of screening 
tools should be tested in different environments. Ideally, 
this would take the form of prospective studies linked 
to clinically meaningful outcomes, although numerous 
study designs could potentially yield important infor-
mation. These studies should look at triggered clinical 
actions which could be diagnostic or therapeutic, and 
whose correlation to a variety of clinically important out-
comes would be determined. Research should character-
ize construct or predictive validity of any screening tool 
including sensitivity, specificity, positive predictive value 
and negative predictive value. Studies should consider a 
variety of clinically important outcomes.
How do we identify septic shock?
What is known Septic shock occurs in the setting of a 
physiologic state of hypoperfusion. Sepsis 3 defines septic 
shock as “a subset of sepsis in which underlying circula-
tory and cellular/metabolic abnormalities are profound 
enough to substantially increase mortality [1].” Based 
upon a large database analysis and a Delphi process, the 
Sepsis 3 taskforce identified clinical criteria for septic 
shock as (a) hypotension, (b) requiring vasopressors and 
(c) a lactate > 2 [107]. While lactate typically correlates 
with perfusion abnormalities, it may also be associated 
with abnormal metabolism. Further, while Sepsis 3 (and 
previously Sepsis 1 and 2) includes definitions without 
recommendations for management, the Surviving Sepsis 
Campaign Guidelines give differential antibiotic recom-
mendations for sepsis as compared to septic shock, often 
based on very low certainty of evidence [3].
Gaps in knowledge/critique of evidence Consensus as to 
what defines shock is lacking. Although many clinicians 
characterize shock by perfusion indices, this does not 
provide a clear definition based on mechanisms. Further, 
the clinical criteria in Sepsis 3, while based upon large 
database analysis, were not unanimously agreed upon 
by the taskforce. Although there was a clearly articulated 
rationale for why the clinical criteria for septic shock 
required hypotension, vasopressors and an elevated lac-
tate (significantly higher mortality than any of these in 
isolation), many in the community continue to believe 
that shock should be defined as hypotension/vasopres-
sors OR elevated lactate, rather than AND. In addition, 
many locations throughout the world cannot measure 
lactate, which leads to the question of how one identifies 
septic shock at the bedside if a clinician cannot measure 
lactate. Further, there is limited evidence comparing the 
metabolic and circulatory abnormalities between sepsis 
and septic shock, and it remains unsettled whether septic 
shock is truly a unique entity or simply a manifestation of 
a greater severity of sepsis.
Future directions Research should address the funda-
mental question of whether septic shock is a disorder 
that is distinct from sepsis. If it is, efforts should address 
proxies for septic shock that have predictive validity for 
important outcomes or construct validity for a helpful 
clinical entity. These proxies could be correlated to clini-
cal presentation in an effort to identify a unique group 
of high risk patients. Models could be created from large 
databases and then prospectively validated in larger 
groups of patients. The impacts for diagnosis, treat-
ment and outcomes should be prospectively assessed. 
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Importantly, investigation should address the question 
of whether septic shock needs to be treated differently 
than sepsis outside of the institution of vasopressors. 
Investigation should not rely on an outcome (mortality) 
that is both the independent variable (used when creat-
ing the definitions to differentiate the two entities) and 
the dependent variable (the most common outcome used 
in clinical intervention studies). Finally, the clinical cri-
teria for septic shock in Sepsis 3 should be prospectively 
validated.
What in‑hospital clinical information is associated 
with important outcomes in septic patients?
What is known Clinical criteria used to identify sepsis in 
patients with suspected infection are derived from the 
association between mortality, length of ICU stay, and 
a discharge diagnosis of sepsis. The construct validity is 
based on limited, but clinically available, criteria (SOFA 
or qSOFA score ≥ 2, suspected infection) and validated 
to a few outcomes. At the bedside, clinicians draw on a 
larger collection of data to make diagnostic and thera-
peutic decisions. Ultimately, practitioners make clinical 
decisions, such as limiting life-sustaining therapies and 
deciding to transfer patients into or out from an ICU, 
based on an impression of prognosis.
Gaps in knowledge/critique of evidence The new Sepsis 
3 definition has substantially improved construct valid-
ity for the concept of sepsis [114]. SOFA is an older tool 
that predicts mortality in patient populations, although 
some elements of the SOFA score are outdated (such as 
“renal dose” dopamine). In addition, qSOFA has fairly 
robust validity in predicting mortality and prolonged stay 
in patients prior to ICU admission (although its accuracy 
is lower in the ICU) [112, 115–117]. However, both mor-
tality and increased length of ICU stay are themselves 
influenced by clinical decision making. Many important 
clinical outcomes, such as cognitive dysfunction and last-
ing organ dysfunctions, have not been studied. It is also 
unclear if the variables or specific elements in SOFA need 
updating. The pathobiology of many (if not most) adverse 
outcomes in the ICU is not described.
Future directions Research is needed both in improv-
ing which clinical information is utilized and in assessing 
patient-centric outcomes beyond mortality and length 
of ICU stay (understanding that these continue to be 
critically important outcomes). This is far reaching as it 
requires enhanced understanding of what is most impor-
tant out of a massive amount of data readily available to 
the ICU team (essentially everything in the electronic 
medical record), data that exist but might not be readily 
available (heart rate variability as an example) and data 
that are currently not available (a moment by moment 
assessment of a patient’s immune status). Further, it 
requires a conversation between clinicians and patients/
families as to what outcomes are most important. 
Answering the two components of this research ques-
tion will therefore require studies ranging from (but not 
limited to) (a) animal modeling, (b) new study designs, 
(c) big data approaches, (d) creation of new technolo-
gies, and (e) survey and face-to-face meetings to under-
stand what outcomes are most valued. Measures should 
be assessed individually and as multiple, interactive vari-
ables, to establish relationships between different organ 
dysfunctions.
Administration/epidemiology
Which is the optimal model of delivering sepsis care?
What is known The way in which ICUs and their larger 
hospitals and healthcare systems are organized and man-
aged affects quality and efficiency in sepsis care. Further, 
both early recognition and early intervention in sepsis 
saves lives. Performance improvement efforts for sep-
sis are associated with improved patient outcomes. An 
example of this is the Surviving Sepsis Campaign bun-
dles, in which rapid antibiotic administration and fluid 
resuscitation are associated with lower mortality [4, 118–
121]. Sepsis performance improvement programs should 
optimally have multiprofessional representation (physi-
cians, nurses, advanced practice providers, pharmacists, 
respiratory therapists, nutrition support specialists, 
administrators). Successful programs should include pro-
tocol development and implementation, targeted metrics 
to be evaluated, data collection, and ongoing feedback 
to facilitate continuous performance improvement. Ide-
ally, sepsis performance improvement programs should 
be sustained over time with repeated assessment of key 
metrics and additional intervention if there is a failure 
to “hold the gain”. Despite many success stories, many 
ICUs, hospitals and healthcare systems have been slow 
to adopt recommended sepsis protocols or initiate qual-
ity improvement programs because of a myriad of imple-
mentation challenges and/or financial concerns.
Gaps in knowledge/critique of evidence Although both 
bundles (intended for quality improvement) and guidelines 
(intended to help guide practice) are based on the best 
available evidence, they are frequently not supported by 
high-quality evidence. While it is known that adaptation 
of process of care to different health care systems around 
the globe is highly variable, there is a lack of understanding 
both in the extent of this variability and its causes. Within 
bundles, even if beneficial in aggregate, this does not mean 
that each component has equivalent efficacy (or any effi-
cacy) and whether other critical elements are missing 
entirely that would potentially change outcome.
Future directions Research towards understanding 
which systems of sepsis screening and care delivery are 
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most beneficial and cost-effective in a wide variety of 
patient care environments is critical. This should not be 
limited to the ICU but include the emergency depart-
ment and the wards (and potentially both pre-hospi-
tal emergency care and outpatient facilities for sepsis 
screening as well) [122, 123]. These can be intra-location 
delivery systems (i.e. ICU-specific, ED-specific), intra-
hospital, intra-health care system or regionalized (such 
as in trauma care in many countries). Methods of deter-
mining and then tracking optimal communication, tran-
sitions of care, and multidisciplinary coordination of care 
will likely be critical to this effort. Determining the best 
tool to detect the at-risk patient with optimal sensitiv-
ity and specificity is equally important. Finally, research 
should attempt to determine the relative importance of 
each bundle component and elements should be added, 
deleted or modified based upon these results.
Which is the epidemiology of sepsis susceptibility 
and response to treatment?
What is known Sepsis is a heterogeneous syndrome. The 
phenotype of sepsis in an individualized patient is influ-
enced by both specifics of the infectious process and the 
host response of an individual patient. Different infec-
tions will impact the host differentially, and even within 
a single organism, different virulence factors will induce 
distinct responses. The host response is equally variable, 
and different genetic, epigenetic, and cellular/subcellu-
lar factors lead patients to respond very differently to the 
identical therapy [124–130].
Gaps in knowledge/critique of evidence Although Sep-
sis 3 is an intellectual advance, it continues to be non-
specific, and does not make distinctions between either 
type of infection or host response [1, 2, 131–134]. An 
urgent need thus exists to better characterize different 
subgroups of sepsis, assuming they exist (which is likely). 
The field of precision medicine as it relates to sepsis is 
still in its infancy, so an ability to characterize patients 
based on their biological profile rather than clinical crite-
ria alone is not currently possible at the bedside.
Future directions Research should improve the epide-
miological information of sepsis in different subgroup 
of patients. In the short-term, this might be based upon 
factors that are currently identifiable such as transplant, 
oncohematological, elderly, etc. In the longer term, this 
should be more individualized and more biological in 
nature. Factors that require tailoring of therapy should 
be assayed. This should include both pathogen factors 
and host factors (phenotypes, endotypes, omics, real 
time assessment of immune function). Ideally, this would 
allow clinicians to prophylax against sepsis as well as 
treat the syndrome in an individualized manner.
It is possible to stratify the risk of sepsis based on biomarker 
panels?
What is known Biomarkers are laboratory assessments 
used to detect and characterize diseases and improve 
clinical decision making. A reliable biomarker for sep-
sis would assist with earlier diagnosis, improve risk 
stratification, or improve decision making for care in 
septic patients [135–137]. Risk stratification and prog-
nostication in sepsis is of particular importance because 
high-risk patients may benefit from earlier clinical inter-
ventions, whereas low-risk patients may benefit from not 
undergoing unnecessary procedures. Prognostication in 
sepsis is currently done mostly via clinical criteria (e.g., 
organ dysfunction and/or presence of shock) and blood 
lactate levels. While numerous biomarkers have been 
evaluated in sepsis, none has sufficient accuracy to be 
utilized in clinical practice. The most commonly used 
biomarker in septic patients is procalcitonin, but its util-
ity (though still debated) is predominantly to discontinue 
antibiotics in septic patients when levels fall. Preliminary 
studies suggest stratification using omics techniques are 
able to identify high risk patients.
Gaps in knowledge/critique of evidence It is unclear if 
the absence of acceptable predictive validity in a single 
biomarkers means (a) we have not yet found the correct 
biomarker, (b) we have inadequately studied the cor-
rect biomarker, or (c) there is no single biomarker that is 
predictive in sepsis, owning to its heterogeneity. Omics 
approaches that can generate a “molecular fingerprint” 
for risk validation and possibly treatment are promis-
ing; however, published studies have not been validated. 
Further the best approach (genomics, transcriptomics, 
proteomics, metabolomics, epigenetic approaches, etc.) 
are unclear both from accuracy and feasibility in terms of 
timeliness and cost.
Future directions Research should continue into 
whether a single or multiple biomarker have acceptable 
predictive value to predict development or progression 
of sepsis, prognosis from sepsis (including need for ICU 
admission) and/or response to therapy. Existing prelimi-
nary studies with omics, endotypes and epigenetic anal-
ysis should be validated by research groups outside of 
those who developed them. Additional research should 
also be performed to refine and expand existing models 
and/or to create new biomarker/molecular fingerprints 
in sepsis.
Post‑ICU
What is the attributable long‑term morbidity and mortality 
from sepsis?
What is known As recognition of sepsis increases globally 
and compliance with best practice improves, the short-
term mortality from sepsis appears to be improving, 
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although the degree to which this is occurring is con-
troversial [131]. While this is obviously encouraging, 
this leads to an increase in the number of sepsis survi-
vors globally, which represents an additional burden to 
the heath-care systems in terms of rehabilitation, long-
term care and support to caregivers. It is important here 
to distinguish between acute mortality directly related 
to the initial insult and late (or post-acute) mortality in 
patients who survive after hospital discharge. The cur-
rent knowledge about late sepsis-attributable mortality 
is limited. Select older data coming from high income 
countries suggest that sepsis survivors have worse long-
term outcomes [138, 139]. A recent systematic review 
of 43 studies, among which only 16 had control arms 
to allow assessment of attributable mortality, failed to 
clearly demonstrate a causal relationship between sepsis 
and post-acute mortality [140]. This systematic review 
raised the alternative hypothesis that the increased mor-
tality after sepsis was probably related to the pre-existing 
disease comorbidity. The review’s conclusion was sub-
sequently challenged by two well-designed studies. One 
study showed that mortality was increased, compared 
with matched non-hospitalized controls, non-septic 
infected hospitalized patients and patients admitted with 
sterile inflammatory conditions [141]. Another study 
demonstrated that septic patients had higher mortality 
than matched controls from the general population and 
subjects who were hospitalized for a non-septic cause 
[142]. Data from newer cohorts with appropriate con-
trols have also shown that sepsis survivors have a higher 
risk of hospital readmission which is associated with an 
increased risk of death [143–145]. Since some of these 
readmissions are caused by ambulatory care sensitive 
conditions [143], it is possible that some percentage of 
these readmissions is preventable.
It is useful to organize the broad domain of morbidity 
in terms of the Post-Intensive Care Syndrome framework 
[146], which divides post-critical illness morbidity into 
(a) cognitive impairment; (b) emotional impairments; 
and (c) physical disability; as well as (d) increases in spe-
cific disease states. There are data to suggest sepsis causes 
an acute and enduring worsening of cognitive function 
among survivors [147, 148]. There are conflicting data 
on emotional impairment with some studies suggest-
ing increased rates of psychiatric diagnoses [149] and 
others suggesting little change in rates of self-reported 
depressive symptoms [150] albeit with elevated pre-sep-
sis symptom burden. Multiple cohorts describe a clear 
high burden of psychological problems among survivors, 
including anxiety and post-traumatic stress disorder, 
regardless of whether it is pre-existing, unmasked, or 
truly caused by the sepsis or other critical illness [151–
154]. These data are indirect, however, as they come from 
non-septic critically ill patients or exclusively elderly sep-
tic patients. Disability rates also appear to be increased 
for years in survivors of sepsis compared to their pre-
ICU levels, at least among older Americans and are high 
in many populations, driving poor measured health-
related quality of life [148, 155–158]. While there have 
been no systematic efforts to map the specific conditions 
for which septic patients are at increased risk, there are 
suggestions of increased rates of malignancy, readmis-
sions for a new sepsis episode, high rates of new cardio-
vascular diseases and residual immune dysregulations 
[142, 143, 159–163]. Many septic patients develop new 
comorbidities such as chronic kidney failure, the mech-
anisms of which may be different than in patients with 
non-septic acute kidney injury [164]. Other potential 
sepsis-associated long term consequences include frailty 
and an altered microbiome [165, 166]. Unfortunately, 
many studies in this domain are vulnerable to biases from 
insufficient characterization of pre-sepsis levels and tra-
jectories of illness [167].
Gaps in knowledge/critique of evidence The specific 
burden of sepsis morbidity is inadequately character-
ized, particularly in terms of treatable conditions and 
competing risks. In addition, while significant contri-
butions have been made regarding the four elements of 
post intensive care syndrome, the literature is still con-
flicting at times, incomplete at times, and at risk for bias. 
The impact of sepsis on caregivers is also inadequately 
described, including ways in which caregivers provide 
effective support, and the ways in which supporting car-
egivers may improve the support of patients. Finally, low 
and middle-income countries harbor 85% of all sepsis 
cases. Although mortality rates are higher, thus generat-
ing less survivors, the burden to the heath-care system 
has not been characterized, which may lead to an even 
higher burden given that these systems are less prepared 
in terms of rehabilitation capacity, chronic care facilities 
and support to caregivers.
Future directions More studies are needed to assess 
the attributable mortality of sepsis (both short-term and 
late) assessing pre-illness trajectory, confounding factors, 
and appropriate control groups. Studies using advanced 
matching techniques to distinguish par subgroups of sep-
sis from those of other ill and/or critically ill patients at 
risk of acquiring sepsis are needed. More comprehensive 
studies are required to determine to what extent sepsis 
causes all elements of the post intensive care syndrome 
and whether this differs between sepsis and other causes 
of ICU admission. Next, understanding the causes of 
readmission could potentially lead to the determination 
of preventable causes. Finally, since pre-, intra- and post-
hospital resources may play a crucial role in potentially 
preventable causes of long-term morbidity and mortality, 
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studies need to be performed in diverse settings, and not 
just high income countries.
What are the predictors of sepsis long‑term morbidity 
and mortality?
What is known Evidence regarding the extent to which 
sepsis causes late morbidity and mortality is generally low 
level and has limited the measurement of a causal rela-
tionship between different groups. In 16 studies reported 
in a systematic review with non-sepsis controls, the main 
predictor variables for post-acute mortality were age, 
male sex, tobacco use, health-care associated pneumonia, 
use of immunosuppressant drugs, HIV infection, cancer, 
previous cardiovascular or cerebrovascular disease and 
the degree of organ dysfunction [140]. However, even in 
well-controlled studies, it is difficult to identify among 
these factors those related to the sepsis-attributable mor-
tality. A recent controlled study showed that late excess 
mortality was higher in patients with 3 or more organ 
dysfunctions, even after adjusting for acute mortality 
differences [141]. Another recent study observed these 
[141] effects were significantly higher in male patients, 
younger patients, those with higher Charlson Comor-
bidity Index scores, those with higher numbers of organ 
failure, those admitted to intensive care units, those with 
shock, and those who required mechanical ventilatory 
support [142].
Gaps in knowledge/critique of evidence The causal rela-
tionship between sepsis and specific subsequent mor-
bidity has been inadequately characterized. Composite 
outcomes such as quality of life may dilute the ability 
to measure specific prognostically or mechanistically 
relevant associations due to poor reliability [168]. It is 
unclear to what extent acute burden of illness under cur-
rent supportive technology is correlated with longer-
term burden of illness. For instance, some conditions 
(e.g. acute hypoxic respiratory failure) may be difficult to 
manage in the inpatient setting, but not strongly associ-
ated with worse long-term outcomes among those who 
survive the acute setting [169]. In addition, many studies 
do not distinguish between predictors that are prognosti-
cally relevant among survivors and those predictors that 
are mechanistically relevant, which can lead to selection 
bias.
Future directions More studies are needed to assess 
the sepsis attributable mortality assessing pre-illness 
trajectory, confounding factors, and appropriate con-
trol groups both in well-resourced setting and resource-
limited settings. Approaches to rapidly retrospectively 
characterize patients’ pre-sepsis illness and morbidity 
trajectory are needed, particularly methods that can use 
indirect measures such as patterns of past hospitaliza-
tions, nursing home use, activity as recorded in personal 
devices (e.g. smartphones, fitness trackers or proxy 
reports [170–172]. Studies using advanced match-
ing techniques to distinguish subgroups of sepsis from 
those of other ill and/or critically ill patients at risk of 
acquiring sepsis are also needed. Finally identification of 
potential modifiable risk factors is important to design 
interventional trials.
Are there potential in‑hospital interventions that can impact 
long term outcomes?
What is known An implication of the data reviewed in 
questions 1 and 2 in this section is that sepsis-attribut-
able late morbidity and mortality might be amenable to 
in-hospital interventions. There is strong clinical and 
physiologic plausibility that interventions considered 
as best practice with respect to short-term outcomes 
will also translate into improved long-term mortal-
ity and morbidity. Credible in-hospital interventions 
for which long-term consequences should be consid-
ered include (but are not limited to) (a) sepsis screen-
ing and detection strategies, (b) ICU triage and use of 
ICU, about which there is conflicting evidence in terms 
of short-term mortality in the United States and France, 
at least among elderly patients [173, 174], (c) alterna-
tive antibiotic regimens, including empiric strategies, 
culture guidance, and de-escalation strategies, and the 
ABCDEF bundle [175]. Ultimately, however, our knowl-
edge about the relationship between in-hospital inter-
ventions and long-terms outcomes is limited, which 
precludes any definitive statements about the impact of 
such interventions.
Gaps in knowledge/critique of evidence There is no sys-
tematic review assessing this issue and concrete evidence 
linking in-hospital intervention and long-term outcomes 
is generally lacking. In addition, there are no data from 
low and middle-income countries. Since previous stud-
ies suggest that compliance with best practice standards 
might be lower in these settings, potential associations 
between in-hospital interventions and long-term out-
comes need to be specifically addressed in low and mid-
dle-income countries.
Future directions Epidemiological studies assessing 
the association of in-hospital interventions are needed 
with adequate controls and controlling of confound-
ing factors and selection bias. In addition, long-term 
follow-up of patients undergoing randomized trials in-
hospital may help to clarify whether intervening in the 
hospital impacts long-term outcome. Currently, most 
studies do not examine long-term outcomes because of 
either cost or feasibility issues, yet the opportunity to 
determine the lasting (or transient) impact of in-hospi-
tal interventions is crucial in understanding long-term 
patient well-being.
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Are there potential post‑discharge interventions that can 
improve outcomes?
What is known The optimal strategy for rehabilitation 
programs and post discharge outpatient clinics aiming to 
improve quality of life and long-term sepsis mortality is 
unknown. Two trials that addressed this issue in critically 
ill patients (not specifically with sepsis) failed to show 
improved outcomes [176, 177]. Hospital readmissions for 
ambulatory care sensitive conditions are more common 
after sepsis than after matched controls, suggesting that 
effective outpatient care might have an impact in reduc-
ing re-hospitalization and, consequently, might influ-
ence long-term morbidity and mortality [143]. Despite a 
relative paucity of evidence to support their use, there is 
growing use of practices targeting the critically ill, which 
will, by definition, capture many septic patients. In the 
United Kingdom, the NICE guidelines recommend a 
post-ICU follow-up review after 2–3 months for all adult 
patients who stayed in critical care for more than 4 days 
and were at risk of morbidity [178]. They also state that 
health care systems should ensure that any adult who 
has had a critical care stay can be reassessed if they self-
refer at any time. A model integrating early, time-limited 
post-ICU follow-up (including nurses, physicians, physi-
cal therapists, pharmacists, social workers, and peer sup-
port) is also being disseminated across Scotland [179]. In 
the United States, there is growing interest in both post-
ICU clinics and post-ICU peer support models [180]. 
A growing number of United States hospitals report 
focusing on sepsis as part of the Centers of Medicare 
and Medicaid Services (CMS) program Partnership for 
Patients that aims to a 12% reduction in 30-day readmis-
sions [181].
Gaps in knowledge/critique of evidence There is no sys-
tematic review assessing this issue, nor have most of the 
currently adopted models been subject to rigorous com-
parative effectiveness research. In addition, to our knowl-
edge there are no data from low and middle-income 
countries.
Future directions Studies aiming to assess the impact 
of rehabilitation and the long- term follow up of septic 
patient patients in rehabilitation clinics are needed.
Basic/translational science
What mechanisms underlie sepsis‑induced cellular 
and sub‑cellular dysfunction?
What is known Specific functional abnormalities have 
been reported in essentially all tissues/organs follow-
ing sepsis. Some evidence suggests that sepsis causes a 
global defect in a basic sub-cellular function that could 
lead to the development of dysfunction in many different 
cell types irrespective of their specific function or loca-
tion. For example, a defect in mitochondrial oxidative 
phosphorylation has been demonstrated in multiple cell 
types [182–184]. The resulting energy deficit could dis-
able cell-specific functions. Conversely, each cell or type 
of cell may develop a specific defect or manifest dysfunc-
tion in a unique manner. For example, secretory func-
tion in monocytes and lymphocytes increases, elevating 
cytokine production [185], while elaboration/release of 
surfactant or surfactant proteins by type 2 pulmonary 
epithelial cells [186–188] or of hormones by endocrine 
or pituitary cells decrease [189–192]. Similarly, apopto-
sis increases in lymphocytes, dendritic cells and the gut 
epithelium, while apoptosis is delayed following sepsis 
in neutrophils (and is unaffected in multiple other cell 
types) [193–196]. Finally, dysfunction in a single type of 
cell that is present in virtually all organs could under-
lie cell- and organ-specific dysfunction. For example, 
endothelial cells, which are present in all tissues, actively 
produce inflammatory mediators and coagulation inter-
mediaries during sepsis, and contribute to sepsis-induced 
vascular dysfunction and leak [197, 198].
Gaps in knowledge//future directions Does a global 
defect that is shared by multiple cell types underlie all 
forms of sepsis-induced cellular dysfunction? Are there 
unique mechanisms of dysfunction that are specific to 
different types of cells? Do cells of similar embryologic 
origin (e.g., epithelium) become dysfunctional in ways 
that differ from other types of cells? Do cells with similar 
functions (e.g., elaboration/release of proteins, lipids etc.) 
develop unique forms of dysfunction that differ from that 
of cells with different basic functions (e.g., all cells that 
contract)? Since endothelial cells are present in virtu-
ally all organ systems and may directly modulate organ 
function, does endothelial cell dysfunction underlie dys-
function in other organ system? Conversely, because 
crosstalk occurs between virtually all organ systems and 
may directly modulate organ function, is there are an 
overarching method in which cells communicate to cause 
dysfunction on other organ systems? Finally, what are 
the mechanisms triggering these cellular alterations and 
what could be the interplay with tissue hypoperfusion?
How does sepsis alter bio‑energetics and/or metabolism 
(both enhancement and failure)?
What is known Sepsis dramatically alters bio-energetics 
and/or metabolism [199, 200]. Sepsis increases meta-
bolic rate, as reflected in oxygen consumption and overall 
substrate utilization [201]. However, this is paradoxically 
associated with a reduction in ATP utilization in many 
tissues, which occurs in concert with maintenance of ATP 
abundance, suggesting that the decreased use reflects 
an attempt to conserve ATP availability [202, 203]. 
Decreased activity in electron transport chain complexes 
I, III, IV and ATP synthase has also been demonstrated 
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[183, 184]. Sepsis is also known to alter substrate prefer-
ence, with a decrease in the utilization of glucose (glu-
cose intolerance) relative to fat and protein [204, 205]. 
As a result, septic patients tend to be hyperglycemic. In 
later stages oxidation of fatty acids may also be impaired, 
as reflected in elevated serum levels of lipoproteins, free 
fatty acids and triglycerides. Glycolysis is favored over 
oxidative phosphorylation despite adequate oxygen avail-
ability (“aerobic glycolysis”, sometimes called the War-
burg Effect) [206–208]. There is accelerated catabolism of 
skeletal muscle and perhaps smooth muscle as well [209]. 
In addition, micronutrient (e.g., vitamins, trace metals) 
effects are also impaired, reflecting either deficiency or 
altered activity [210, 211]. In addition, abnormalities are 
noted in the level and/or effectiveness of most hormones 
in sepsis [192].
Gaps in knowledge/future directions Are changes in 
energetics observed in all cells or are they cell-type spe-
cific? Are defects affecting energetics present only in 
mitochondria or are there changes in other sub-cellular 
structures? What mechanisms mediate alterations in 
oxidative phosphorylation? What underlies the altered 
activity in specific electron transport chain complexes? 
What mechanisms alter sepsis-induced changes in path-
way (e.g., glycolysis, beta-oxidation, nitrogen cycle), sub-
strate (e.g., carbohydrate, fat, protein, micronutrient), 
and/or cell-specific (e.g., cardiomyocyte, hepatocyte etc.) 
metabolism? What mechanisms underlie sepsis-induced 
defects in endocrine activity? How does sepsis affect 
brain circuits that control metabolism? Since cytokines 
alter metabolism in incompletely understood ways, 
how do cytokines alter metabolic pathways (and which 
ones are responsible)? Do metabolic pathways influence 
inflammation, and if so, how?
How does sepsis (and/or approaches used to manage sepsis) 
alter phenotypes and interactions in the host microbiome 
and do alterations in the microbiome effect outcomes?
What is known The microbiome contains 40 trillion 
organisms, the same number of cells as in the host patient 
[212]. While the majority of bacterial species and diver-
sity of the microbiome reside within the gut lumen, the 
microbiome includes all microorganisms residing within 
(mouth, lungs, gut) or on (skin) the host. Microbial diver-
sity is enormous with 1000 different species of bacteria 
and over 2 million bacterial genes [212, 213]. Sepsis leads 
to a rapid (within 6  h) decrease in microbial diversity 
[214]. Whereas the most common microbe makes up 25% 
of the microbiome in healthy patients, a massive diver-
sity crash causes results in the most common microbe 
making up 95% of the microbiome in ICU patients [215]. 
These changes appear to result from both the underlying 
disorder (sepsis) and its treatment (antibiotics), which 
by definition alter the microbiome [216–222]. Further, 
microbes alter their virulence in response to both the 
internal host environment (availability of phosphate) and 
treatments in critically ill patients (opiates) [223–225]. 
Bacteria in pre-clinical models of sepsis can be tricked 
into “believing” that the host environment is non-toxic, 
preventing the development of virulence factors that 
would ordinarily occur in sepsis, leading to survival 
advantage in septic rodents [226]. Microbes also possess 
the capacity for quorum sensing in which individual cells 
can work together to collectively respond to the environ-
ment [227, 228].
Gaps in knowledge/future directions What mecha-
nisms underlie the specific, sepsis-induced changes in the 
microbiome? Are these reversible? If so, how? How do 
alterations in the microbiome affect the host response? 
Which components of the microbiome are responsible? 
Is it possible to restore a healthy microbiome in the set-
ting of clinical therapies that continue to alter the micro-
biome? Does the site of bacteria within the microbiome 
make a difference and can specific host locations be tar-
geted (for instance, the respiratory microbiome)? Does 
restoring a healthy microbiome improve outcomes in 
patients (note: this is more of a clinical question than a 
basic science question since fecal microbial transplant, 
probiotics, prebiotics, synbiotics and selective decon-
tamination of the digestive disease system are currently 
in clinical use in select environments)?
What mechanisms initiate, sustain and terminate recovery?
What is known Aside from therapy targeting the spe-
cific infection in the ICU, treatment for sepsis is non-
specific and supportive. In spite of this, it is implicitly 
understood by clinicians that cells and organ systems 
must recover over time in sepsis survivors despite the 
absence of therapy aimed at cellular/organ recovery. The 
study of mechanisms behind recovery in sepsis has only 
recently become an area of focus in basic/translational 
sepsis research, and thus relatively little is understood. 
Intrinsic to recovery is the return of function at subcel-
lular, cellular, and multicellular/organ levels, and within 
the immune, metabolic, endocrine, intestinal, vascular, 
neurologic, etc. systems. Recovery may be affected by 
specific mediators and systems that participate in the ini-
tiation and development of sepsis-associated responses. 
Examples include lipids (resolvins, lipoxins, maresins, 
prostanoids), autophagy, miRNAs, exosomes, and neu-
ronal activity [190, 229–235].
Gaps in knowledge/future directions What mechanisms 
and specific mediators are important in recovery? What 
metabolic, energetic immune, endocrine, intestinal, 
neuronal and vascular, etc. pathways mediate recovery 
from dysregulated cellular and subcellular function? Can 
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sub-cellular, cellular and/or tissue/organ- specific dys-
function be reversed or mitigated by promoting recovery 
pathways and can the magnitude and time frame of this 
recovery be accelerated?
Conclusion
This work complements two recent publications on 
research priorities in sepsis. A 2017 research agenda by 
11 international experts in septic shock listed 10 topics 
to undergo testing over the next 10 years [236]. A 2015 
research roadmap by 13 international authors proposed 
research topics on a wide array of subjects ranging from 
epidemiology to molecular diagnostics [237]. It is logical 
that there should be some overlap between the priorities 
in the different manuscripts, and although each of the 
potential questions for this manuscript were developed 
independently of the other two, each previously enumer-
ated priority is proposed in some fashion in the current 
recommendations. This suggests there is some degree of 
international consensus regarding sepsis research pri-
orities, and multiple international groups are actively 
performing research on these priorities. However, the 
priority list detailed herein additionally includes top-
ics that have been little covered in past efforts, including 
post-ICU and is broader in scope.
Ultimately, although our understanding of sepsis 
has greatly increased over the past 20  years, mortality 
remains unacceptably high. The reasons for this are mul-
tifactorial. Significant gaps in knowledge translation from 
existing evidence to the bedside exist, and efforts aimed 
to translating best practice to the bedside will almost 
assuredly result in better outcomes. However, even if all 
existing best practice standards were followed, signifi-
cant knowledge gaps remain on a wide array of issues. 
By taking a maximally inclusive view of priorities in adult 
sepsis, we hope this overview will serve as a catalyst for 
research that needs to be performed in sepsis.
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